Illumina reported third-quarter results on Oct. 29 that included 4.7% organic revenue growth outside of China (versus its 4.5% prior guidance) and 7% adjusted earnings per share growth to $1.44 (versus its $1.33-$1.38 prior guidance). Management also raised its 2026 guidance.
Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth opportunities for Illumina even without owning all of Grail.
Disruptive technology risks could threaten Illumina's industry-leading sequencing platform, leading to market share losses.
|
Metric
|
ILMN
|
TMO
|
|---|---|---|
Price/Earnings (Normalized) | 45.82 | 31.21 |
Price/Book Value | 11.41 | 4.72 |
Price/Sales | 7.99 | 5.50 |
Price/Cash Flow | 27.40 | 24.99 |
|
Metric
|
ILMN
|
TMO
|
|---|---|---|
Quick Ratio | 1.79 | 1.23 |
Current Ratio | 2.63 | 1.81 |
Interest Coverage | 11.48 | 5.52 |
|
Metric
|
ILMN
|
TMO
|
|---|---|---|
Return on Assets (Normalized) | 15.38% | 8.32% |
Return on Equity (Normalized) | 36.69% | 17.48% |
Return on Invested Capital (Normalized) | 20.12% | 10.45% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|%d$D&%? | LOCK|GFx | $258B | |||
| Danaher Corp
DHR
| LOCK|!z$<VwB | LOCK|^p | $163B | |||
| Agilent Technologies Inc
A
| LOCK|?%?YBWCD | LOCK|yX | $49B | |||
| Waters Corp
WAT
| LOCK|fJRRgJP | LOCK|b>R | $45B | |||
| IQVIA Holdings Inc
IQV
| LOCK|pwc!&n@ | LOCK|s<k>Y | $44B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|x&>n%&? | LOCK|@@^ | $43B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|zFh@%JnV | LOCK|w%g&! | $34B | |||
| Labcorp Holdings Inc
LH
| LOCK|DgmCJfL | LOCK|M^GR% | $29B | |||
| Quest Diagnostics Inc
DGX
| LOCK|ZR%>$>G | LOCK|>k&P | $28B |
United States